Angiostatic therapies are now routinely embedded in the daily clinical management of cancer.
Introduction
Angiogenesis inhibitors have firmly entered the current clinical practice for treatment of cancer [1] [2] [3] .
Many of these agents, such as bevacizumab/Avastin ® , sunitinib/Sutent ® , and erlotinib/Tarceva ® , have provided new treatment options for patients with e.g. renal cell carcinoma (RCC) 3 , nonsmall cell lung carcinoma 4 , colorectal carcinoma 1 , and gastrointestinal stromal tumors 2 . However, when these drugs are used as monotherapies or in addition to existing treatment strategies, their contribution to patient survival is rather limited. This limited activity is most likely due to the heterogeneity that exists among patients, as well as in tumors 5 , limited dose schedules due to drug toxicity and the development of drug-induced resistance 6 . It is very likely, and also generally realized, that considerable improvement of cancer therapy should be achievable through the combination of different treatment strategies. Similarly, the identification of a superior angiostatic strategy could come from combining different vascular targeting and angiostatic regimens. Like most intrinsic cell functions, angiogenesis is regulated through a system of highly robust and redundant cell signaling pathways aimed to maintain normal cell function 7, 8 . Neutralizing one of these pathways will likely lead to compensation by the cell through the upregulation of other pathways in an attempt to maintain normal function 9 . These redundant cell signaling pathways, which play a role to facilitate the development of drug resistance, may also increase the likelihood of identifying combinations of drugs which can synergistically inhibit angiogenesis 10 . Although it seems a daunting task to find an optimal combination therapy due to the enormous number of possible options, much can be learned from recent experiences in combining different therapies.
This experience originates from efforts to combine different angiogenesis inhibitors, but also from research on the combination of angiogenesis inhibitors with other treatment approaches with intrinsic angiostatic potential, such as chemo-, radio-, immuno-and photodynamic therapy ( Fig.   1 ). Without trying to be exhaustive, this review will give an overview of what is known about the development of angiostatic combination therapies and the challenges that are faced in trying to improve treatment of disease.
Combination of angiogenesis inhibitors
Design of an effective angiostatic strategy may be achieved by combining drugs, which inhibit a broad array of different angiogenic signaling pathways. Designing such a combination therapy, however, is not trivial, as two compounds may exert synergistic, additive or even antagonistic interactions on each other. In addition, synergy can also be dose-dependent, so while two therapies result in synergistic activity in a given circumstance, this activity may be lost when drug doses and ratios are varied. Furthermore, the sequencing of drugs can also be extremely important, as has been demonstrated in the treatment of RCC, where an effective sequence of drugs can be ineffective when the order of administration is changed 11 . Combination of drugs in the clinic is often based on the previous success of drugs when used as monotherapy or in combination with other drugs. It is clear that such an approach seems to rely on trial and error and, most importantly, fully ignores the biology of tumor and endothelial cells. However, combinations are continuously tested in preclinical research and promising strategies are subsequently tested in the clinic.
Since the identification of the first angiogenesis inhibitors in the early 1990s, reports can be found on the combination of these initial angiostatic compounds. It was realized that certain inhibitors act through different signaling pathways, potentially giving synergism between the drugs. An early example of such a study was the identification of synergism between angiostatin and endostatin 12 , two drugs with rather unknown working mechanisms. Later, a study with the galectin-1 targeting drug anginex with angiostatin showed clear synergism 13 . More studies resulted in the conclusion that the combination of angiogenesis inhibitors is heavily associated with toxicity, e.g. hypertension, hypothyroidism, hand-foot syndrome, and fatigue (TKI-associated) and immunosuppression, and non-infectious pneumonitis (mTOR associated) [16] [17] [18] Another option of designing angiostatic combination therapies is with the combined use of conventional treatment strategies that have an intrinsic angiostatic activity. It has been known for some time now that certain chemotherapeutic compounds have an angiostatic effect as well 19 , especially when given at low dose long term regimens 20, 21 . Radiotherapy and photodynamic therapy have also been known to have a major effect on the tumor vasculature, suggesting the potential for its successful use in combination with angiogenesis inhibitors 22, 23 . In addition, the reciprocal interactions between the immune system and angiogenesis suggest that angiogenesis inhibition can be reinforced by immunotherapy Since metronomic therapy consists of frequent and well tolerated low-dose chemotherapy administration, combination with other treatment modalities may be of clinical benefit 25 . It was previously proposed that by combining metronomic therapy with angiogenesis inhibitors, enhanced anti-tumour efficacy could be achieved 20, 21 . In recent years, many preclinical studies confirmed this hypothesis. For example, a study that evaluated the combination of metronomic topotecan and pazopanib in a murine model of human ovarian carcinoma showed that the anti-tumour activity of topotecan was significantly enhanced by pazopanib 28 . Another study showed that metronomic gemcitabine in combination with sunitinib inhibited primary tumour growth and metastasis in an orthotopic mice model for pancreatic carcinoma, while both individual treatments were less effective 29 .
Apart from the conventional chemotherapeutics used for metronomic therapy, ruthenium compounds were also studied for their activity in combination with angiogenesis inhibitors. KP-1339 for instance, showed synergistic activity in vitro, as well as in vivo models in combination with sorafenib. It was proposed that NKP-1339 potentiates the anticancer activity of sorafenib by increased apoptosis and G2/M arrest 30 .
Several clinical trials have been performed, or are still in progress, to further investigate the potential of metronomic chemotherapeutics in combination with anti-angiogenic agents. A study assessing the combination of metronomic capecitabine and cyclophosphamide in combination with bevacizumab and erlotinib in adult patients with metastatic HER2-negative breast cancer
showed an overall clinical benefit of 75%, a prolonged median time to progression 31 . This treatment regimen was well tolerated and showed only mild toxicity. In contrast, a study that evaluated the combination of metronomic vinorelbine in combination with bevacizumab in adult patients with metastatic breast cancer was cancelled due to a lack of efficacy, though the therapy was very well-tolerated 32 . In addition, a phase II trial was conducted that tested the combination of bevacizumab with metronomic cyclophosphamide in patients with recurrent ovarian carcinoma and revealed significant activity of the treatment regimen 33 . Currently under clinical evaluation is the combination of pazopanib and metronomic cyclophosphamide in patients with recurrent ovarian carcinoma (PACOVAR trial, NCT01238770) 34 .
Increasing preclinical and clinical data suggest a great potential for combining anti-angiogenic chemotherapeutics with angiogenesis inhibitors. A major advantage could be a well tolerable treatment regimen due to low drug doses. However, more clinical trials are necessary to reveal the true value of this anti-angiogenesis strategy.
Angiogenesis inhibition in combination with radiotherapy
In general, anti-angiogenic therapy has the potential to induce structural and functional normalization of tumor vasculature. Additionally, angiostatic drugs may improve the tumor microenvironment 35 . During this normalization window, the efficacy of conventional treatments is significantly enhanced, including concomitant radiotherapy (RT) [35] [36] [37] . Hence, administration of angiostatic drugs may increase the effectiveness of radiotherapy.
When RT is combined with angiogenesis inhibitors, a synergistic effect has been shown. For example, Dings et al. 36 described the synergistic effect of combining RT and a direct antiangiogenic peptide (anginex) or bevacizumab. As a result of normalized tumor vasculature, improved oxygen delivery is achieved, and hypoxic conditions are eliminated,, resulting in a tumor microenvironment with enhanced therapeutic potential for radiotherapy. It is generally realized that the effects of high-and low-dose radiotherapy vary. Sofia Vala et al. 38 found that low-doses of radiotherapy (0.5 Gy) induced rapid phosphorylation of several endothelial cell proteins, including VEGFR-2 and induced VEGF production in hypoxia mimicking conditions. This effect may explain why they found that low-dose irradiation actually enhanced angiogenesis and endothelial cell migration. Hence, low-dose radiotherapy may result in a progressive tumor growth and increased metastatic spread, in contrast to high-dose radiotherapy 39 .
The clinical applicability of combining radiotherapy with anti-angiogenic drugs has also been studied. Especially bevacizumab was subject to several clinical trials in different types of tumor tissue, including head & neck and colorectal tumors 40, 41 . The phase I clinical trial by Czito et al. 41 showed promising results. This group combined bevacizumab, capecitabine, oxaliplatin and radiation therapy for treatment of rectal cancer. Of the 11 included patients, 6 experienced a significant response. In the remaining 5 patients, the disease was progression-free during this study. Despite these encouraging results, some patients did experience minor adverse side effects, including bleeding and duodenal ulcers. Gasparini et al. who continued research on the combination of bevacizumab and radiotherapy in a phase II trial, also found a clinical benefit of additional angiostatic treatment 37 . Overall, most phase I/II trials with bevacizumab and radiotherapy found a decrease in tumor progression, although toxicity of this combination remains an issue.
The combination of anti-angiogenic and radiotherapy has also been tested in brain tumors. For example, Knisely et al. 42 combined thalidomide, an inhibitor of bFGF activity, with whole brain radiotherapy. Unfortunately, these trials showed no increased in overall survival in the combination therapy groups. Moreover, 48% of patients were excluded due to severe side effects.
The authors argue that angiostatic drugs that directly act on endothelium may be more effective. It is evident that future research is required to determine the benefit of combining radiation with angiostasis. Keibeuker et al. provided a comprehensive review on the combination of radiotherapy with anti-angiogenesis 22 .
Angiogenesis inhibition in combination with immunotherapy
Immunotherapy is a rapidly growing field in the treatment of cancer. It involves stimulation of the components of either the innate or adaptive immune system to target tumor cells. This strategy not only enhances anti-tumor immunity but has also been shown to affect tumor angiogenesis.
Immunotherapy is considered a double-edged sword since the immune system regulates both pro- Additionally, we have previously investigated the potential of prolonging the angio-occlusive effects of verteporfin-PDT through its combination with angiogenesis inhibition in both physiologic angiogenesis in the chicken chorioallantoic membrane 68 and in tumor angiogenesis in human ovarian carcinoma (A2780) xenografts in the same model 69 .
In the latter study, we reported the synergistic inhibition of tumor growth through the combination of sub-optimal doses of three anti-angiogenic TKIs (axitinib, sorafenib and sunitinib) and low-dose verteporfin-PDT 69 .
In 
Conclusion
The current overview makes it clear that there are major opportunities to improve angiostatic treatment. However, it also becomes evident that there are an almost infinite number of possibilities for the development of efficient angiostatic treatment regimens. Because of this enormous parametric space it is obvious that the current clinical trial and error approach will not result in optimal improvement of angiostatic treatment. Therefore it may be necessary to call upon mathematical modeling systems to systematically screen for optimal combinations. Several initiatives in this regard have been proposed. For example, to predicting the effects of combining anti-angiogenic and chemotherapeutic agents 73, 74 .
